Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms (vol 13, 1223282, 2023)

被引：0
|
作者：
Grunwald, Viktor [1 ,2 ]
Powles, Thomas [3 ,4 ]
Eto, Masatoshi [5 ]
Kopyltsov, Evgeny [6 ]
Rha, Sun Young [7 ]
Porta, Camillo [8 ]
Motzer, Robert [9 ]
Hutson, Thomas E. [10 ]
Mendez-Vidal, Maria Jose [11 ]
Hong, Sung-Hoo [12 ]
Winquist, Eric [13 ]
Goh, Jeffrey C. [14 ,15 ]
Maroto, Pablo [16 ]
Buchler, Tomas [17 ,18 ]
Takagi, Toshio [19 ]
Burgents, Joseph E. [20 ]
Perini, Rodolfo [21 ]
He, Cixin [22 ]
Okpara, Chinyere E. [23 ]
McKenzie, Jodi [24 ]
Choueiri, Toni K. [25 ]
机构：
[1] Univ Hosp Essen, Clin Med Oncol, Essen, Germany
[2] Univ Hosp Essen, Clin Urol, Essen, Germany
[3] Queen Mary Univ London, Barts Canc Inst, London, England
[4] Queen Mary Univ London, Royal Free Hosp, London, England
[5] Kyushu Univ, Dept Urol, Fukuoka, Japan
[6] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia
[7] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Dept Internal Med, Seoul, South Korea
[8] Univ Bari A Moro, Dept Biomed Sci & Human Oncol, Bari, Italy
[9] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[10] Texas Oncol, Med Oncol, Dallas, TX USA
[11] Hosp Univ Reina Sofia, Dept Oncol, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain
[12] Catholic Univ Korea, Seoul St Marys Hosp, Dept Urol, Seoul, South Korea
[13] Univ Western Ontario, Dept Oncol, London, ON, Canada
[14] ICON Res, South Brisbane, Qld, Australia
[15] Univ Queensland, St Lucia, Qld, Australia
[16] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[17] Charles Univ Prague, Dept Oncol, Prague, Czech Republic
[18] Thomayer Univ Hosp, Prague, Czech Republic
[19] Tokyo Womens Med Univ, Dept Urol, Tokyo, Japan
[20] Merck & Co Inc, Global Clin Dev, Rahway, NJ USA
[21] Merck & Co Inc, Clin Res, Rahway, NJ USA
[22] Eisai Inc, Biostat, Nutley, NJ USA
[23] Eisai Ltd, Clin Res, Hatfield, England
[24] Eisai Inc, Clin Res, Nutley, NJ USA
[25] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
来源：
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词：
renal cell carcinoma; lenvatinib; pembrolizumab; sunitinib; bone metastases; liver metastases; lung metastases; sarcomatoid histology;
D O I：
10.3389/fonc.2023.1343027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Characteristics and management of major adverse events in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab based on results from the CLEAR trial
    Motzer, R.
    George, S.
    Merchan, J. R.
    Hutson, T. E.
    Song, X.
    Perini, R. F.
    Xie, R.
    Bapat, U.
    Puente, J.
    ONKOUROLOGIYA, 2023, 19 (02): : 29 - 40
  • [42] Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Porta, Camillo
    Alekseev, Boris
    Rha, Sun Young
    Choueiri, Toni K.
    Mendez-Vidal, Maria Jose
    Hong, Sung-Hoo
    Kapoor, Anil
    Goh, Jeffrey C.
    Eto, Masatoshi
    Wang, Jinyi
    Pan, Janice
    Asfaw, Alemseged Ayele
    He, Cixin Steven
    Mody, Kalgi
    Cella, David
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    Taylor, Matthew H.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina E.
    Wu, Jane
    Stepan, Daniel E.
    Shumaker, Robert C.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1154 - +
  • [44] LEAP-002: phase 3 study of first-line lenvatinib plus pembrolizumab for patients with advanced hepatocellular carcinoma
    Llovet, Josep
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina
    Chen, Erluo
    Dubrovsky, Leonid
    Siegel, Abby
    Zhu, Andrew
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [45] Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Choueiri, T. K.
    Eto, M.
    Kopyltsov, E.
    Rha, S. Y.
    Porta, C. G.
    Motzer, R.
    Gruenwald, V.
    Hutson, T. E.
    Mendez-Vidal, M. J.
    Hong, S-H.
    Winquist, E.
    Goh, J. C. H.
    Maroto, P.
    Buchler, T.
    Takagi, T.
    Rodriguez-Lopez, K.
    Xing, D.
    Smith, A. D.
    Powles, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S683 - S685
  • [46] Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC)
    Rini, Brian I.
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem
    Waddell, Tom
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris
    Soulieres, Denis
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    McDermott, Raymond S.
    Perini, Rodolfo F.
    Markensohn, Julia
    Molife, L. Rhoda
    Zhang, Yiwei
    Nebozhyn, Michael
    Loboda, Andrey
    Vajdi, Amir
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib plus pembrolizumab (L plus P) in the phase 3 CLEAR trial.
    Keizman, Daniel
    Bedke, Jens
    Staehler, Michael D.
    Matveev, Vsevolod B.
    George, Saby
    Hutson, Thomas E.
    Vaishampayan, Ulka N.
    Merchan, Jaime R.
    Eto, Masatoshi
    Rha, Sun Young
    Waddell, Tom
    Sabbatini, Roberto
    Barthelemy, Philippe
    Burgents, Joseph E.
    Ren, Min
    Brown, Ian
    Saal, Hakim
    Choueiri, Toni K.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 531 - 531
  • [48] Lenvatinib and pembrolizumab in patients with metastatic papillary renal cell carcinoma: A phase 2 pilot study.
    Tsimafeyeu, Ilya
    Sultanbaev Sr, Alexander
    Vilkov, Sergey
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 109 - 109
  • [49] Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma
    Wentink, Madelon Q.
    Verheul, Henk M. W.
    Pal, Sumanta K.
    George, Saby
    Voortman, Johannes
    Danchaivijitr, Pongwut
    Adelaiye, Remi
    Poslinski, Diane
    Groman, Adrienne
    Hutson, Alan
    Pili, Roberto
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E1 - E9
  • [50] Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
    Lee, J. -L.
    Ahn, J. -H.
    Lim, H. Y.
    Park, S. H.
    Lee, S. H.
    Kim, T. M.
    Lee, D. -H.
    Cho, Y. M.
    Song, C.
    Hong, J. H.
    Kim, C. -S.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2108 - 2114
12345